Sage Journals: Discover world-class research

Retricted access

Other

First published 2011-08

EMA Approves Revision of Label for Tysabri

Biotechnology Law Report

Retricted access

Research article

First published 2011-2

An approach to natalizumab hypersensitivity: a case series of induction of tolerance

Marie Camacho-Halili, Roxanne George, Malcolm Gottesman [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2021-4

Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program

Heinz Wiendl, Tim Spelman, Helmut Butzkueven [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2021-3

Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri ® Observational Program (TOP)

Helmut Butzkueven, Maria Trojano, Ludwig Kappos [...]

Multiple Sclerosis Journal

Retricted access

Other

First published 2009-10

Medicare Taking Close Look at Erythropoietin Coverage;Elan-Biogen Deal for Tysabri Violated

Biotechnology Law Report

Open access

Research article

First published 2021

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

Helmut Butzkueven, Ludwig Kappos, Tim Spelman [...]

Therapeutic Advances in Neurological Disorders

Open access

Research article

First published 2019

The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri ® PharmacoEconomics (TyPE) Study

B Polistena, F Spandonaro, R Capra [...]

Global & Regional Health Technology Assessment: Italian;Northern Europe and Spanish

Retricted access

Other

First published 2009-11

Severe relapses after the first infusion of natalizumab in active relapsing—remitting multiple sclerosis

Francesca Rinaldi, Paola Perini, Massimiliano Calabrese [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2014-7

Smokers run increased risk of developing anti-natalizumab antibodies

AK Hedström, L Alfredsson, M Lundkvist Ryner [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2011-12

Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse

C Papeix, R Depaz, A Tourbah [...]

Multiple Sclerosis Journal

Search results